Eisai ^Investors

Eisai is a pharmaceutical company that focuses on human healthcare, specializing in oncology and neurology. They research and deliver medicines for patients with dementia-related diseases and neurodegenerative diseases. Eisai operates in business groups and provides products and services to patients and their families under any healthcare system. They have achieved global development and commercialization of their antibody drug complex, farletuzumab ecteribulin (FZEC), and have ended their strategic partnership with Bristol Myers Squibb.